Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05711719 · ClinicalTrials.gov registry record · Phase 2
Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT05711719: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT05711719 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 45 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05711719, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
Coronary vascular dysfunction is one of the "final common pathways" for the impact of multiple cardiovascular risk factors. The investigators will conduct a randomized, double-blind placebo-controlled study in individuals with the metabolic syndrome and baseline coronary vascular dysfunction to evaluate the impact of vericiguat, a stimulator of soluble guanylyl cyclase, on coronary vascular function using non-invasive cardiac magnetic resonance imaging.
Interventions
- DRUG Placebo
- DRUG Vericiguat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2023-06-16 |
| Est. Completion | 2025-11-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05711719
The ClinicalTrials.gov registry entry for NCT05711719 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05711719 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05711719 about?
NCT05711719 is a clinical study titled "Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction". Coronary vascular dysfunction is one of the "final common pathways" for the impact of multiple cardiovascular risk factors. The investigators will conduct a randomized, double-blind placebo-controlled study in individuals with the metabolic syndrome and baseline coronary vascular dysfunction to eval...
What is the current status of trial NCT05711719?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2023-06-16. Estimated completion is 2025-11-18.
What interventions are being tested in trial NCT05711719?
The interventions under investigation include: Placebo (DRUG), Vericiguat (DRUG).
Who is sponsoring clinical trial NCT05711719?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.